Press Release

Distributing Agreement for Clenafin/Jublia in KoreaMay 31, 2016

Tokyo, May 31, 2016 – Kaken Pharmaceutical Co., Ltd. (“Kaken”, head office Bunkyo-ku, Tokyo; President and Representative Director Tetsuo Onuma) announced today that Kaken and Dong-A ST Co., Ltd. (“Dong-A”, head office Dongdaemun-gu, Seoul; President and Representative Director Soo-Hyoung Kang) concluded an exclusive distribution agreement for the topical formulation for Onychomycosis “Clenafin / Jublia” [“Product”, (generic name: efinaconazole)] in Korea.


According to the agreement, Kaken hereby grant to Dong-A the exclusive right for development and sales of the Product in Korea.
Dong-A expect to obtain an approval of the Product at 2017 in Korea.


About Dong-A

Company name :
Dong-A ST Co., Ltd.
President :
Soo-Hyoung Kang
Head Quarter :
Seoul, Republic of Korea
Capital :
KRW 40.2 billion (USD 365 million)
Sales :
KRW 567.9 billion (USD 5,162 million)

Back to list